Aaron Prendergast

Queen Mary University of London

Papers

1

Total Citations

20

H-Index

1

About

Dr. Aaron Prendergast is a leading urologic oncologist whose research centers on the intersection of focal therapy and robotic surgery for prostate cancer, with a particular focus on optimizing treatment outcomes for men with recurrent or residual disease. His most notable contribution is the landmark RAFT (Robotic surgery After Focal Therapy) trial, which prospectively evaluated the safety and toxicity of salvage robotic prostatectomy following prior focal ablation. This work, published in 2021 and already garnering 20 citations, provides critical evidence that robotic surgery remains a viable and safe option after focal therapy fails, addressing a key clinical dilemma in prostate cancer management. By systematically documenting perioperative outcomes and complication rates, Prendergast has helped define the therapeutic pathway for patients who experience disease recurrence, a growing population as focal therapy becomes more widespread. His research directly informs surgical decision-making and patient counseling, bridging the gap between minimally invasive ablation and definitive surgical salvage. Through the RAFT trial and related studies, Prendergast has established himself as a key voice in the evolving landscape of prostate cancer treatment sequencing, demonstrating that even after focal therapy fails, patients can still achieve favorable outcomes with robotic salvage surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
20
Total Citations
20
Avg Citations/Paper
🏆 Most Cited Paper
Outcomes of the RAFT trial: robotic surgery after focal therapy
20 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 14
🏛 Institutions: Queen Mary University of London

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago